title: The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease.
abstract: Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons and the aggression of alpha Synuclein (αS) in the brain. Drosophila mutants and transgenes have provided a platform to understand the mechanistic insight associated with the degenerative diseases. A number of polyphenols have been reported to inhibit the αS aggregation resulting in the possible prevention of PD. The involvement of free radicals in mediating the neuronal death in PD has also been implicated. In the present study, the effect of Nordihydroguaiaretic acid (NDGA) was studied on the climbing ability of the PD model Drosophila expressing normal human alpha synuclein (h-αS) in the neurons. These flies exhibit locomotor dysfunction as the age progresses. NDGA at final concentration of 0.01, 0.1, 0.5, and 1μl/ml was supplemented with the diet and the flies were allowed to feed for the 24 days. NDGA at 0.01 μl/ml did not showed any significant delay in the loss of climbing ability of PD model flies. However, NDGA doses at 0.1, 0.5, and 1.0 μl/ml showed a dose dependent significant (p < .05) delay in the loss of climbing ability of PD model flies as compared to the untreated PD flies. The results suggest that the NDGA is potent in delaying the climbing disability of PD model flies and also supports the utility of this model in studying PD symptoms.
authors.affiliation: Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, UP, India. yasir_hasansiddique@rediffmail.com
authors.forename: Yasir Hasan
authors.initials: YH
authors.lastname: Siddique
authors.forename: Gulshan
authors.initials: G
authors.lastname: Ara
authors.forename: Smita
authors.initials: S
authors.lastname: Jyoti
authors.forename: Mohammad
authors.initials: M
authors.lastname: Afzal
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D019587:Dietary Supplements; D004195:Disease Models, Animal; D059290:Dopaminergic Neurons / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D029721:Drosophila Proteins / Q000037:antagonists & inhibitors; D004331:Drosophila melanogaster; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D008124:Locomotion / Q000187:drug effects*; D009637:Masoprocol / Q000494:pharmacology / Q000627:therapeutic use*; D009154:Mutation; D010300:Parkinson Disease / Q000378:metabolism / Q000517:prevention & control*; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D051844:alpha-Synuclein / Q000037:antagonists & inhibitors*
chemical_list: D029721:Drosophila Proteins; D005609:Free Radicals; D010936:Plant Extracts; D051844:alpha-Synuclein; D009637:Masoprocol